AgingResearch.NewsJoin free

NESFATIN-1

Intervention

1 paper2 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

  • 1 lab
  • Animals1

Outcomes

2

Blood-brain barrier dysfunction

downin mice1

1 study

  1. NESFATIN-1 decreases blood-brain barrier dysfunction in mice.

    “NF-1 mitigated BBB dysfunction and enhanced the expression of claudin 5 and ZO-1 in the brains of AD mice.”

    Animalsin the brains of AD mice

    Nesfatin-1 ameliorates blood-brain barrier dysfunction in Alzheimer's disease by targeting VEGF-R1 and reducing cellular senescence in brain vascular endothelial cells

    Translational psychiatry3 Sep 2025

FLT1

downin mice1

1 study

  1. NESFATIN-1 decreases FLT1 in mice.

    “NF-1 administration lowered VEGF-R1 expression in the brain cortex of AD mice.”

    Animalsin the brain cortex of AD mice

    Nesfatin-1 ameliorates blood-brain barrier dysfunction in Alzheimer's disease by targeting VEGF-R1 and reducing cellular senescence in brain vascular endothelial cells

    Translational psychiatry3 Sep 2025

More on FLT1

Latest

Related